查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1715817

生物模拟市场：按产品、交付模式、应用和最终用户划分－2025-2030 年全球预测

Biosimulation Market by Offering, Delivery Model, Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年生物模拟市场价值将达31亿美元，2024年将达35.5亿美元，复合年增长率为14.60%，2030年将达80.7亿美元。

主要市场统计数据
基准年2023年 31亿美元
预计2024年 35.5亿美元
预测年份 2030 80.7亿美元
复合年增长率（%） 14.60%

生物模拟已成为重塑生命科学格局的重要工具。该领域将先进的计算演算法与生物数据相结合，以简化和加强研究工作，为传统实验程序提供更准确、更具成本效益的替代方案。如今，创新公司正在转向能够预测治疗结果、模拟药物交互作用和优化临床试验设计的系统。透过利用先进的模拟工具，市场开发正在加快开发週期、改善决策并降低药物发现和开发风险。随着数位技术的广泛使用和对高效调查方法的需求不断增长，生物模拟已成为克服科学和经济障碍的重要工具。在这种环境下，预测分析和复杂生物模型的结合对于推进临床前和临床试验至关重要。随着产业越来越倾向于数据主导策略，当今的生物模拟策略为突破性进展铺平了道路，有可能改变患者照护并提高世界各地的行业标准。

改变生物模拟市场

在科技的快速进步和调查方法的模式转移的推动下，生物模拟环境正在经历巨大的变革时期。传统的实验室实验正逐渐被数位和计算替代方案所取代，这些替代方案不仅提高了速度，还增加了分析深度。自动化、机器学习和高保真模拟模型的结合使研究人员能够以前所未有的清晰度探索复杂的生物现象。这种转变的特征是从依赖经验数据收集转向预测模型，从而实现更快的假设检验和明智的决策。此外，模拟平台的进步提供了多种工具来满足药物研究不同方面的独特要求。因此，该行业正在采用更灵活的框架，其中迭代设计和虚拟测试是业务蓝图的核心，而不仅仅是互补的活动。监管观点的改变和数位模拟结果的日益接受进一步强调了这种转变，使得生物模拟成为现代治疗方法创新和研究中越来越不可或缺的一部分。

生物模拟分割及其意义的详细分析

市场以多种方式细分，让人们得以一窥生物模拟的高阶层面。根据所提供的服务，市场细分为服务和软体，服务市场进一步细分为合约服务和内部服务。另一方面，软体类别包括各种专业工具，如分子建模和模拟软体、PBPK建模和模拟软体、PK/PD建模和模拟软体、毒性预测软体、研究设计软体等。另一个维度是基于交付模式，区分所有权和订阅模式，这反映了不同的投资策略和存取偏好。此外，基于应用的细分突出了药物开发和药物发现的双重重点。药物开发本身分为临床试验和临床前试验等细微差别，后者进一步细分为 ADME/Tox 和 PK/PD 考虑。相较之下，药物发现强调目标识别和检验以及先导物识别和优化等技术。最后，基于最终用户的细分将市场分为受託研究机构、製药和生物技术公司、监管机构和研究机构，每个组织在推动生物模拟价值链方面发挥独特的作用。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 专注于个人化医疗研究
      • 监管机构核准使用生物模拟技术促进安全药物的开发
    • 限制因素
      • 生物模拟安装和技术开发价格上涨
    • 机会
      • 模拟解决方案的持续进步将增强新型生物疗法
      • 增加对药物开发和测试的投资
    • 任务
      • 复杂性和缺乏产生准确结果的意识
  • 市场区隔分析
    • 我们提供的服务：生物模拟越来越多地使用提供模型建构、模拟、分析和视觉化平台的软体。
    • 交付模式：由于生物模拟的前期成本较低，所有权模式越来越受到青睐。
    • 应用：扩大生物模拟在临床试验的应用
    • 最终用户：製药和生物技术公司越来越多地采用生物模拟
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章 生物模拟市场（按类型）

  • 服务
    • 合约服务
    • 内部服务
  • 软体
    • 分子建模与模拟软体
    • PBPK建模与模拟软体
    • PK/PD建模和模拟软体
    • 毒性预测软体
    • 测试设计软体

第七章 生物模拟市场（依交付模式）

  • 所有权模式
  • 订阅模式

第八章 生物模拟市场（按应用）

  • 药物开发
    • 临床试验
    • 临床前试验
      • ADME/毒性
      • PK/PD
  • 药物研发
    • 线索辨识与优化
    • 目标识别和检验

第九章 生物模拟市场（按最终用户）

  • 合约研究组织
  • 製药和生物技术公司
  • 监管机构
  • 研究机构

第 10 章：美洲生物模拟市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第 11 章亚太地区生物模拟市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第 12 章欧洲、中东和非洲生物模拟市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023年市场占有率分析
  • 2023年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Advanced Chemistry Development, Inc.
  • Aitia
  • Allucent
  • Biomed Simulation, Inc.
  • BioSimulation Consulting Inc.
  • Cadence Design Systems, Inc.
  • Cell Works Group, Inc.
  • Certara, Inc.
  • Chemical Computing Group ULC
  • Crystal Pharmatech Co., Ltd.
  • Cytel Inc.
  • Dassault Systemes SE
  • ICON PLC
  • In Silico Biosciences, Inc.
  • INOSIM Software GmbH
  • Instem PLC
  • Model Vitals
  • Physiomics PLC
  • Quotient Sciences Limited
  • Resolution Medical
  • Schrodinger, Inc.
  • Simulations Plus, Inc.
  • Thermo Fisher Scientific Inc.
  • VeriSIM Life
  • VIRTUALMAN
  • Yokogawa Electric Corporation
Product Code: MRR-2D64BA93AB17

The Biosimulation Market was valued at USD 3.10 billion in 2023 and is projected to grow to USD 3.55 billion in 2024, with a CAGR of 14.60%, reaching USD 8.07 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 3.10 billion
Estimated Year [2024] USD 3.55 billion
Forecast Year [2030] USD 8.07 billion
CAGR (%) 14.60%

Biosimulation has emerged as a vital tool that is reshaping the life sciences landscape. This discipline blends advanced computational algorithms with biological data to streamline and enhance research activities, offering a more precise and cost-effective alternative to traditional experimental procedures. Today, innovative organizations are leaning into systems that can predict outcomes, simulate drug interactions, and optimize clinical trial designs. By leveraging sophisticated simulation tools, the market is witnessing accelerated development cycles, improved decision-making, and reduced risk in drug discovery and development. The proliferation of digital technologies and increased demand for efficient research methodologies have propelled biosimulation into the spotlight as a key enabler for overcoming scientific and financial hurdles. In this environment, the fusion of predictive analytics with complex biological models is proving indispensable in advancing both preclinical and clinical studies. With the industry increasingly leaning on data-driven strategies, today's biosimulation strategies pave the way for breakthroughs that hold the potential to transform patient care and elevate industry standards across the globe.

Transformative Shifts in the Biosimulation Landscape

The biosimulation landscape is undergoing profound transformations, fueled by rapid technological advancements and a paradigm shift in research methodologies. Traditional laboratory experiments are gradually making way for digital and computational alternatives that offer not only speed but also a greater depth of analysis. The integration of automation, machine learning, and high-fidelity simulation models is empowering researchers to explore complex biological phenomena with unprecedented clarity. These transformative shifts are characterized by a move from reliance on empirical data collection towards predictive modeling, enabling faster hypothesis testing and more informed decision-making. Moreover, the evolution of simulation platforms is providing versatile tools that cater to the unique requirements of various aspects of pharmaceutical research. As a result, the industry is embracing a more agile framework where iterative design and virtual testing are not just complementary activities, but central to the operational blueprint. The changes in regulatory perspectives and the growing acceptance of digitally simulated outcomes further underline this transition, making biosimulation an increasingly integral part of modern therapeutic innovation and research.

In-Depth Analysis of Biosimulation Segmentation and Its Implications

The market is segmented in multiple ways which offer a window into the sophisticated layers of biosimulation. When viewed based on the offering, the market divides into services and software, where services are further broken down into contract services and in-house services, whereas the software category encompasses a range of specialized tools including molecular modeling and simulation software, PBPK modeling and simulation software, PK/PD modeling and simulation software, toxicity prediction software, and trial design software. Another dimension is based on the delivery model, which distinguishes between ownership models and subscription models, reflecting varied investment strategies and access preferences. Moreover, application-based segmentation highlights the dual focus on drug development and drug discovery. Drug development itself spirals into nuances such as clinical trials and preclinical testing, with the latter further delineated into ADME/Tox and PK/PD considerations. In contrast, drug discovery emphasizes techniques such as lead identification and optimization alongside target identification and validation. Lastly, segmentation based on end-user categorizes the market according to contract research organizations, pharmaceutical and biotechnology companies, regulatory authorities, and research institutes, each playing their distinct role in driving the biosimulation value chain.

Based on Offering, market is studied across Services and Software. The Services is further studied across Contract Services and In-House Services. The Software is further studied across Molecular Modeling & Simulation Software, PBPK Modeling & Simulation Software, PK/PD Modeling & Simulation Software, Toxicity Prediction Software, and Trial Design Software.

Based on Delivery Model, market is studied across Ownership Models and Subscription Models.

Based on Application, market is studied across Drug Development and Drug Discovery. The Drug Development is further studied across Clinical Trials and Preclinical Testing. The Preclinical Testing is further studied across ADME/Tox and PK/PD. The Drug Discovery is further studied across Lead Identification & Optimization and Target Identification & Validation.

Based on End-User, market is studied across Contract Research Organizations, Pharmaceutical & Biotechnology Companies, Regulatory Authorities, and Research Institutes.

Regional Dynamics Shaping the Global Biosimulation Market

Regional insights reveal a complex mosaic of opportunities and challenges that are reshaping the biosimulation arena. In the Americas, a blend of strong research institutions and robust funding mechanisms fosters an environment where biosimulation tools are rapidly adopted and refined. The region stands out with its strong regulatory frameworks and strategic partnerships that spearhead innovation. In the Europe, Middle East & Africa region, the convergence of academic research and industrial expertise creates a vibrant ecosystem. Here, well-established pharmaceutical hubs collaborate with technology providers to drive efficiency and bolster regulatory compliance, ensuring that simulation technologies align with regional standards. Meanwhile, the Asia-Pacific region is witnessing significant growth fueled by increasing investments in research and development, a surge in tech-driven startups, and expanding capabilities in digital health. This geographically diverse spread of opportunities underscores the need for tailored strategies that cater to local market dynamics, competitive pressures, and intercultural variations in research methodologies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Industry Leaders Driving Biosimulation Innovation

Industry insights highlight the emergence of several key players who are instrumental in advancing the field of biosimulation. Leaders such as Advanced Chemistry Development, Inc. and Aitia are at the forefront of integrating computational modeling into everyday research routines. Companies like Allucent, Biomed Simulation, Inc., and BioSimulation Consulting Inc. bring specialized expertise that enhances the scope and precision of simulation strategies employed throughout the sector. This is complemented by the innovation drive of Cadence Design Systems, Inc., Cell Works Group, Inc., and Certara, Inc., along with Chemical Computing Group ULC and Crystal Pharmatech Co., Ltd. Additional trailblazers including Cytel Inc., Dassault Systemes SE, ICON PLC, and In Silico Biosciences, Inc. are redefining industry benchmarks. INOSIM Software GmbH, Instem PLC, Model Vitals, and Physiomics PLC, among others like Quotient Sciences Limited, Resolution Medical, and Schrodinger, Inc., further bolster the competitive landscape. The influence of companies such as Simulations Plus, Inc., Thermo Fisher Scientific Inc., VeriSIM Life, VIRTUALMAN, and Yokogawa Electric Corporation cannot be overstated in the ongoing drive towards more efficient, reliable, and transformative biosimulation methodologies.

The report delves into recent significant developments in the Biosimulation Market, highlighting leading vendors and their innovative profiles. These include Advanced Chemistry Development, Inc., Aitia, Allucent, Biomed Simulation, Inc., BioSimulation Consulting Inc., Cadence Design Systems, Inc., Cell Works Group, Inc., Certara, Inc., Chemical Computing Group ULC, Crystal Pharmatech Co., Ltd., Cytel Inc., Dassault Systemes SE, ICON PLC, In Silico Biosciences, Inc., INOSIM Software GmbH, Instem PLC, Model Vitals, Physiomics PLC, Quotient Sciences Limited, Resolution Medical, Schrodinger, Inc., Simulations Plus, Inc., Thermo Fisher Scientific Inc., VeriSIM Life, VIRTUALMAN, and Yokogawa Electric Corporation. Strategic Recommendations for Biosimulation Industry Leaders

For industry leaders, the evolving landscape presents multiple avenues for strategic advancement. It is imperative to invest in next-generation simulation platforms that blend advanced computational power with intuitive user interfaces, thereby enhancing both predictive accuracy and operational efficiency. Fostering partnerships with technology providers can facilitate access to innovative tools while also offering new collaborative research opportunities. Leaders should prioritize dynamic talent development programs that not only cultivate expertise in simulation technologies but also encourage cross-disciplinary synergy between data science, biology, and regulatory affairs. Embracing flexible engagement models such as subscription-based solutions may reduce upfront costs and stimulate broader adoption of emerging technologies. In addition, benchmarking against industry pioneers and integrating real-world data analytics into simulation frameworks can significantly improve overall performance. These actionable approaches offer a roadmap for capitalizing on the transformative potential of biosimulation, ensuring that organizations remain agile, competitive, and well-equipped to address rapidly evolving market requirements.

Conclusion: The Future of Biosimulation in a Rapidly Evolving Landscape

In summary, the biosimulation market is positioned at a critical juncture where technological innovation and strategic foresight converge to redefine research paradigms. The shift from conventional experimental models to data-driven simulation techniques underscores the importance of adaptability and proactive investment in advanced methodologies. A detailed segmentation analysis reveals the multifaceted nature of the market, spanning various offerings, delivery models, applications, and end-users. This complexity is further complemented by distinct regional dynamics and the presence of pioneering companies whose innovative endeavors are setting new industry benchmarks. The insights gained from examining these factors converge to offer a comprehensive understanding of the current state and future trajectory of biosimulation. Ultimately, the key to sustained success in this rapidly evolving field lies in the ability to harness technological advancements, nurture collaborative ecosystems, and maintain a steadfast commitment to continuous improvement and operational excellence.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing emphasis on research of personalized medicine
      • 5.1.1.2. Supportive regulatory approvals for use of biosimulation to enhance the development of safe medicines
    • 5.1.2. Restraints
      • 5.1.2.1. Upscaled prices involved in installations and technique developments for biosimulation
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in simulation solutions to enhance the novel biologic therapies
      • 5.1.3.2. Rising investments for drug developments and drug testings
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness coupled with complexities for creating accurate outcomes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offering: Rising usage of software in biosimulation to provide a platform for model building, simulation, analysis, and visualization
    • 5.2.2. Delivery Model: Growing preference for ownership model in biosimulation owing to its lower initial costs
    • 5.2.3. Application: Increasing application of biosimulation for clinical trials
    • 5.2.4. End-User: Expanding adoption of biosimulation among pharmaceutical & biotechnology companies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biosimulation Market, by Offering

  • 6.1. Introduction
  • 6.2. Services
    • 6.2.1. Contract Services
    • 6.2.2. In-House Services
  • 6.3. Software
    • 6.3.1. Molecular Modeling & Simulation Software
    • 6.3.2. PBPK Modeling & Simulation Software
    • 6.3.3. PK/PD Modeling & Simulation Software
    • 6.3.4. Toxicity Prediction Software
    • 6.3.5. Trial Design Software

7. Biosimulation Market, by Delivery Model

  • 7.1. Introduction
  • 7.2. Ownership Models
  • 7.3. Subscription Models

8. Biosimulation Market, by Application

  • 8.1. Introduction
  • 8.2. Drug Development
    • 8.2.1. Clinical Trials
    • 8.2.2. Preclinical Testing
      • 8.2.2.1. ADME/Tox
      • 8.2.2.2. PK/PD
  • 8.3. Drug Discovery
    • 8.3.1. Lead Identification & Optimization
    • 8.3.2. Target Identification & Validation

9. Biosimulation Market, by End-User

  • 9.1. Introduction
  • 9.2. Contract Research Organizations
  • 9.3. Pharmaceutical & Biotechnology Companies
  • 9.4. Regulatory Authorities
  • 9.5. Research Institutes

10. Americas Biosimulation Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Biosimulation Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Biosimulation Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. ProductLife Group enhances drug development capabilities with IntiQuan acquisition for innovative biosimulation solutions
    • 13.3.2. Cytel's new East Horizon platform enhances adaptive trial design with cloud integration
    • 13.3.3. Orion and Aitia leverage AI-driven digital twins to revolutionize drug discovery in oncology sector
    • 13.3.4. Biosimulation and tumor microenvironment modeling enhance precision of immunotherapy predictions for NSCLC patients
    • 13.3.5. Quantum breakthroughs in biosimulation revolutionize drug discovery with cutting-edge precision modeling
    • 13.3.6. Certara to acquire Chemaxon to enhance drug discovery and biosimulation capabilities
    • 13.3.7. Simulations Plus expands drug development capabilities with USD 100 million acquisition of Pro-Pro-ficiency Holdings, Inc.
    • 13.3.8. Cellworks unveils new CLIA-certified lab in Tennessee enhancing personalized NSCLC treatment with biosimulation technology and expert leadership
    • 13.3.9. ZETA Group acquires majority stake in INOSIM to revolutionize simulation and engineering in biopharma industry
    • 13.3.10. Innovative cloud-based biosimulation partnership between Exploristics and Exonate revolutionizes clinical trial design for retinal disease therapies
    • 13.3.11. Certara launches Pirana Modeling Workbench 23.10.1 with advanced machine learning and new VPC GUI
  • 13.4. Strategy Analysis & Recommendation
    • 13.4.1. Simulations Plus, Inc.
    • 13.4.2. Cadence Design Systems, Inc.
    • 13.4.3. Dassault Systemes SE
    • 13.4.4. Certara, Inc.
    • 13.4.5. Thermo Fisher Scientific Inc.

Companies Mentioned

  • 1. Advanced Chemistry Development, Inc.
  • 2. Aitia
  • 3. Allucent
  • 4. Biomed Simulation, Inc.
  • 5. BioSimulation Consulting Inc.
  • 6. Cadence Design Systems, Inc.
  • 7. Cell Works Group, Inc.
  • 8. Certara, Inc.
  • 9. Chemical Computing Group ULC
  • 10. Crystal Pharmatech Co., Ltd.
  • 11. Cytel Inc.
  • 12. Dassault Systemes SE
  • 13. ICON PLC
  • 14. In Silico Biosciences, Inc.
  • 15. INOSIM Software GmbH
  • 16. Instem PLC
  • 17. Model Vitals
  • 18. Physiomics PLC
  • 19. Quotient Sciences Limited
  • 20. Resolution Medical
  • 21. Schrodinger, Inc.
  • 22. Simulations Plus, Inc.
  • 23. Thermo Fisher Scientific Inc.
  • 24. VeriSIM Life
  • 25. VIRTUALMAN
  • 26. Yokogawa Electric Corporation

LIST OF FIGURES

  • FIGURE 1. BIOSIMULATION MARKET MULTI-CURRENCY
  • FIGURE 2. BIOSIMULATION MARKET MULTI-LANGUAGE
  • FIGURE 3. BIOSIMULATION MARKET RESEARCH PROCESS
  • FIGURE 4. BIOSIMULATION MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL BIOSIMULATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. BIOSIMULATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. BIOSIMULATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOSIMULATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOSIMULATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOSIMULATION MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOSIMULATION MARKET SIZE, BY IN-HOUSE SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOSIMULATION MARKET SIZE, BY MOLECULAR MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOSIMULATION MARKET SIZE, BY PBPK MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOSIMULATION MARKET SIZE, BY TOXICITY PREDICTION SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOSIMULATION MARKET SIZE, BY TRIAL DESIGN SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOSIMULATION MARKET SIZE, BY OWNERSHIP MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOSIMULATION MARKET SIZE, BY SUBSCRIPTION MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOSIMULATION MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BIOSIMULATION MARKET SIZE, BY ADME/TOX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOSIMULATION MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BIOSIMULATION MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BIOSIMULATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOSIMULATION MARKET SIZE, BY REGULATORY AUTHORITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BIOSIMULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. MALAYSIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. TAIWAN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 187. TAIWAN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. THAILAND BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 196. THAILAND BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 197. THAILAND BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. VIETNAM BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 205. VIETNAM BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 223. DENMARK BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 224. DENMARK BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 225. DENMARK BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 232. EGYPT BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 233. EGYPT BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 234. EGYPT BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 241. FINLAND BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 242. FINLAND BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 243. FINLAND BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 250. FRANCE BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 251. FRANCE BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 252. FRANCE BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 259. GERMANY BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 260. GERMANY BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 261. GERMANY BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 268. ISRAEL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 269. ISRAEL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 270. ISRAEL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 271. ISRAEL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 277. ITALY BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 278. ITALY BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 279. ITALY BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 280. ITALY BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 286. NETHERLANDS BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 287. NETHERLANDS BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 288. NETHERLANDS BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 290. NETHERLANDS BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 291. NETHERLANDS BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 295. NIGERIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 296. NIGERIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 297. NIGERIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 298. NIGERIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 299. NIGERIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 300. NIGERIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 304. NORWAY BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 305. NORWAY BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 306. NORWAY BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 307. NORWAY BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 308. NORWAY BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 309. NORWAY BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 310. NORWAY BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 311. NORWAY BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 313. POLAND BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 314. POLAND BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 315. POLAND BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 316. POLAND BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 317. POLAND BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 318. POLAND BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 319. POLAND BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 320. POLAND BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 322. QATAR BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 323. QATAR BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 324. QATAR BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 325. QATAR BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 326. QATAR BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 327. QATAR BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 328. QATAR BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 329. QATAR BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 330. QATAR BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 331. RUSSIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 332. RUSSIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 333. RUSSIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 334. RUSSIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 335. RUSSIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 336. RUSSIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 337. RUSSIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 338. RUSSIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 339. RUSSIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 340. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 341. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 342. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 343. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 344. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 345. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 346. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 347. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 348. SAUDI ARABIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 349. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 350. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 351. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 352. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 353. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 354. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 355. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 356. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 357. SOUTH AFRICA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 358. SPAIN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 359. SPAIN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 360. SPAIN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 361. SPAIN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 362. SPAIN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 363. SPAIN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 364. SPAIN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 365. SPAIN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
  • TABLE 366. SPAIN BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 367. SWEDEN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 368. SWEDEN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 369. SWEDEN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2030 (USD MILLION)
  • TABLE 370. SWEDEN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2030 (USD MILLION)
  • TABLE 371. SWEDEN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2030 (U